A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)GUPTA, Pankaj; MULKEY, Flora; LARSON, Richard A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1311-1320, issn 0167-6997, 10 p.Article

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 9511WETZLER, Meir; SANFORD, Ben L; KURTZBERG, Joanne et al.Blood. 2007, Vol 109, Num 10, pp 4164-4167, issn 0006-4971, 4 p.Article

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma : results of the Cancer and Leukaemia Group B 90102PHILIPS, George K; HALABI, Susan; SANFORD, Ben L et al.BJU international (Papier). 2008, Vol 101, Num 1, pp 20-25, issn 1464-4096, 6 p.Article

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission : Cancer and Leukemia Group B Study 9720BAER, Maria R; GEORGE, Stephen L; ANASTASI, John et al.Journal of clinical oncology. 2008, Vol 26, Num 30, pp 4934-4939, issn 0732-183X, 6 p.Article